All In MedTech

Device Trial Radar · NCT07633847

A Post Market Trial Assessing the Accuracy of Normal Mode Reading vs. ProScan Reading With the NaviCam SB System. This is a Comparison of Retrospectively Obtained Capsule Endoscopy Videos With a New AI Reading Tool; no New Interventions Will be Completed.

Prospective Study Exploring the Difference of AI-Trained Software Compared to Conventional Interpretation Methods in Small Bowel Video Capsule Procedures

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Jun 15, 2028

Study completion Sep 15, 2028

Sponsor

Lead sponsor
AnX Robotica Corp.Not on our public-company list
Sponsor type
Industry
First posted
Jun 8, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NaviCam ProScan is an artificial intelligent (AI) assisted reading tool designed to aid small bowel capsule endoscopy reviewers in decreasing the time to review capsule endoscopy images for adult patients in whom the capsule endoscopy images were obtained for suspected small bowel bleeding.

Conditions

  • Small Bowel Bleeding

Interventions

  • Video capsule endoscopyDevice

    Phase I = Data Collection. The video from the capsule endoscopy procedure will be reviewed and reported by the treating physician. Once the capsule has passed and any adverse events have been collected, there will be no additional patient follow-up.

  • Phase II = Data analysis by Independent ReadersOther

    Independent video capsule readers to review and evaluate the videos from the capsule endoscopy procedure (Phase I), plus the ProScan videos.

  • Phase III = Data Analysis by Expert ReadersOther

    An Expert Panel will read all videos to create a database comparing the Physician results (Phase I) and the ProScan + Physician results (Phase II).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject-level sensitivityTime frame: 24 months
  2. Subject-level specificityTime frame: 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York

  • NYU Grossman School of Medicine

    New York, New York

  • Digestive Health Associates of Texas

    Bedford, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.